LLY compared with ORMP: revenue, margins and what each company keeps, and the suppliers and customers both name

LLYELI Lilly & Co

Mkt capRevenueRevenue

ORMPOramed Pharmaceuticals Inc.

Mkt capRevenueRevenue

Compare

LLYELI Lilly & Co

ORMPOramed Pharmaceuticals Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

LLY

3 of 4at or beyond implied

Reportimpliedrealized× implied

Q3 FY26±5.1%▲+6.63%×1.29

Q2 FY26±6.2%▲+4.86%×0.79

Q1 FY26±5.3%▲+9.80%×1.85

Feb 4 '26±6.1%▲+10.33%×1.69

ORMP

No earnings history for ORMP.

= impliedLLY realized, solidORMP realized, hatchedOne scale, both sides: full bar = 11%× = |realized| ÷ impliedSource: market data

LLYELI Lilly & Co

1,371.32▼−3.29%· post 1,362.06· delayed

Mkt cap$1.3TRevenue$24.4BQ3 FY26Revenue$65.2BFY25

ORMPOramed Pharmaceuticals Inc.

3.92▼−5.14%· post 3.92· delayed

After hoursNov 5 '26delayed

Mkt cap$171.8MRevenue$2MQ1 FY25Revenue—

Compare

After hoursNov 5 '26delayed

LLYELI Lilly & Co

ORMPOramed Pharmaceuticals Inc.

1,371.32▼−3.29%post 1,362.06delayed

Price

3.92▼−5.14%post 3.92delayed

$1.3T

Mkt cap

$171.8M

Q3 FY26$24.4B

Revenue

$2MQ1 FY25

FY25$65.2B

Revenue

—

LLY1,371.32▼−3.29%vsORMP3.92▼−5.14%After hoursNov 5 '26delayed